| GTO ID | GTC3008 |
| Trial ID |
NCT05347485
|
| Disease |
Multiple Myeloma
|
| Altered gene | BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Carvykti|Ciltacabtagene Autoleucel|Cilta-cel|JNJ-68284528 |
| Location approved | US, EU, UK, Japan, Australia, Canada |
| Generation | 2nd |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma |
| Year | 2022 |
| Country | United States |
| Company sponsor | Janssen Scientific Affairs, LLC |
| Other ID(s) | CR109014|68284528MMY2005 |